CAS 880486-59-9

Dacetuzumab

Description:

Dacetuzumab is a monoclonal antibody that targets the CD40 receptor, which is primarily expressed on B cells and plays a crucial role in immune response regulation. This therapeutic agent is designed to enhance the immune system's ability to recognize and destroy cancer cells, making it a candidate for cancer immunotherapy. Dacetuzumab has been investigated in clinical trials for various hematological malignancies and solid tumors, often in combination with other treatments to improve efficacy. Its mechanism of action involves activating immune pathways that can lead to the proliferation of B cells and the production of antibodies against tumor antigens. As a biologic drug, Dacetuzumab is produced using recombinant DNA technology, and its administration typically requires careful monitoring for potential side effects, including infusion reactions and immune-related adverse events. Overall, Dacetuzumab represents a promising approach in the evolving landscape of cancer treatment, focusing on harnessing the body's immune system to combat malignancies.

Formula: Unspecified

Synonyms:

• SGN 40
• Immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal SGN-40 γ1-chain), disulfide with human-mouse monoclonal SGN-40 κ-chain, dimer
• Dacetuzumab
• SGN-CD40
• hu S2C6

Dacetuzumab

CAS: 880486-59-9

Dacetuzumab (SGN 40) is a humanized anti-CD40 monoclonal antibody with antitumor activity for the study of recurrent diffuse large B-cell lymphoma.

Purity: 95.4% (SDS-PAGE); 99.1% (SEC-HPLC) - 95.4% (SDS-PAGE); 99.1% (SEC-HPLC)

Color and Shape: Liquid

Molecular weight: 145.1 kDa

Ref: TM-T76677

Dacetuzumab

CAS: 880486-59-9

Anti-Human CD40 Monoclonal Antibody

Ref: 3D-CLA1178